.jpg "Jonathan Wagner, DO photo")
Pediatric Cardiology, Pediatric Clinical Pharmacologist; Associate Professor of Pediatrics
University of Missouri-Kansas City
Jonathan Wagner, DO, FAAP, graduated with a degree in biochemistry with cum laude latin honors from the University of Missouri-Columbia and received his medical degree with magna cum laude honors from Kansas City University of Medicine and Biosciences. He completed pediatrics residency at Children’s Mercy, followed by a dual fellowship training in pediatric cardiology and pediatric clinical pharmacology. His research involves the impact of genetic variation and development on statin disposition during childhood. His series of pharmacogenomics driven pharmacokinetic studies involving statins has contributed to further understanding of inter-individual variability of statin response in the pediatric population. He is director of the Cardiology Pharmacogenomics Repository (CPR) at Children’s Mercy Kansas City (CMKC). Dr. Wagner has been honored as a finalist for the 2016 AHA Scientific Sessions Council of Cardiovascular Disease in the Young Early Career Award and the CMKC Department of Pediatrics Research Achievement Award in 2018. He has received over 1 million dollars in external funding from the American Heart Association, Thrasher Research Fund, and the National Institutes of Health (NIH) to support his research programs involving pediatric cardiovascular disease and pediatric clinical pharmacology. More recently, his NIH funding from the Frontiers KL2 Clinical and Transitional Mentored Career Development Award has supported his Statin Optimization in Pediatrics program. Dr. Wagner serves on the Advisory Council on Rare Disease and Personalized Medicine for Missouri Health Net division of the Missouri Department of Social Services. He has presented at multiple local and national meetings, has over 25 peer-review publications, authored several books chapters and serves on the editorial board of Clinical and Translational Sciences. Dr. Wagner currently serves as the Division Director of Clinical Pharmacology, Toxicology, and Therapeutic Innovation and remains an active member of the Ward Family Heart Center involved in cardiovascular intensive care, congenital heart disease and cardiovascular genetics.
Disclosure information not submitted.
Tuesday, January 11, 2022
10:00 AM – 11:00 AM ET
.png)